Alkermes plc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
ALKS$46.17+0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2024 and 2023
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| (In thousands, except share and per share amounts) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $291,146 | $457,469 |
| Investments—short-term | 460,522 | 316,022 |
| Receivables, net | 384,528 | 332,477 |
| Inventory | 182,887 | 186,406 |
| Prepaid expenses and other current assets | 91,282 | 98,166 |
| Contract assets | 4,990 | 706 |
| Assets held for sale | — | 94,260 |
| Total current assets | 1,415,355 | 1,485,506 |
| PROPERTY, PLANT AND EQUIPMENT, NET | 227,564 | 226,943 |
| INVESTMENTS—LONG-TERM | 73,148 | 39,887 |
| RIGHT-OF-USE ASSETS | 84,245 | 91,460 |
| INTANGIBLE ASSETS, NET AND GOODWILL | 83,917 | 85,018 |
| DEFERRED TAX ASSETS | 154,835 | 195,888 |
| OTHER ASSETS | 16,503 | 11,521 |
| TOTAL ASSETS | $2,055,567 | $2,136,223 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses | $185,332 | $240,561 |
| Accrued sales discounts, allowances and reserves | 272,452 | 263,641 |
| Operating lease liabilities—short-term | 6,166 | 5,746 |
| Contract liabilities—short-term | 1,249 | 2,730 |
| Current portion of long-term debt | — | 3,000 |
| Liabilities related to discontinued operations | — | 4,542 |
| Total current liabilities | 465,199 | 520,220 |
| LONG-TERM DEBT | — | 287,730 |
| OPERATING LEASE LIABILITIES—LONG-TERM | 69,372 | 75,709 |
| OTHER LONG-TERM LIABILITIES | 56,019 | 49,878 |
| Total liabilities | 590,590 | 933,537 |
| COMMITMENTS AND CONTINGENT LIABILITIES (Note 19) | ||
| SHAREHOLDERS’ EQUITY: | ||
| Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at December 31, 2024 and 2023 | — | — |
| Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 176,670,785 and 172,569,051 shares issued; and 162,176,994 and 166,979,833 shares outstanding at December 31, 2024 and 2023, respectively | 1,767 | 1,726 |
| Treasury shares, at cost (14,493,791 and 5,589,218 shares at December 31, 2024 and 2023, respectively) | (419,255) | (189,336) |
| Additional paid-in capital | 2,860,890 | 2,736,934 |
| Accumulated other comprehensive loss | (1,967) | (3,110) |
| Accumulated deficit | (976,458) | (1,343,528) |
| Total shareholders’ equity | 1,464,977 | 1,202,686 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $2,055,567 | $2,136,223 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.